{
  "docId": "019de072-1970-7036-9d15-9ffed6304914",
  "docSlug": "3db8307bc8c7b92a71fc075519a1ccaf",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 35 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 35,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses color-coded text (orange) to emphasize key clinical findings.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-1970-7036-9d15-9ffed6304914/20",
  "deckHref": "/decks/019de072-1970-7036-9d15-9ffed6304914",
  "deckJsonHref": "/decks/019de072-1970-7036-9d15-9ffed6304914.json",
  "deckAnchorHref": "/decks/019de072-1970-7036-9d15-9ffed6304914#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.12,
        "w": 0.84,
        "x": 0.08,
        "y": 0.74
      },
      "kind": "callout",
      "text": "The Phase III PROpel study is the first combination approach to deliver consistent clinical benefits for patients in the 1L mCRPC setting, irrespective of HRRm status",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19d91eb6-3507-4eeb-a161-079d037efd86",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.78,
        "x": 0.088,
        "y": 0.498
      },
      "kind": "list",
      "text": "Secondary and exploratory endpoints support the treatment benefit of olaparib + abiraterone over placebo + abiraterone in the overall patient population",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "95079496-abff-4cd9-8f57-876e0a3e8da0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.18,
        "w": 0.82,
        "x": 0.088,
        "y": 0.267
      },
      "kind": "list",
      "text": "Olaparib + abiraterone led to a significant and clinically meaningful improvement in rPFS (HR 0.66 [95% CI 0.54–0.81]) over placebo + abiraterone in 1L mCRPC. Benefit observed led to a median rPFS beyond 2 years. Benefit was observed irrespective of HRRm status.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "951701c6-552c-49e9-ac21-916509386a5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.09,
        "w": 0.91,
        "x": 0.088,
        "y": 0.618
      },
      "kind": "list",
      "text": "The safety profile of olaparib + abiraterone was consistent with the safety profile for the individual drugs and there was no detriment to quality of life allowing most patients to stay on therapy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d061236f-70b0-44a4-8358-1f41098a6a1c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.23,
        "x": 0.033,
        "y": 0.067
      },
      "kind": "title",
      "text": "Conclusions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d8819e38-cb2c-487b-83fd-7643fcc029c6",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "9e3bf82c-df72-41dc-b248-4c273b549e57",
      "evidence": "Olaparib + abiraterone led to a significant and clinically meaningful improvement in rPFS",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}